期刊
RESPIRATORY MEDICINE
卷 107, 期 1, 页码 37-46出版社
W B SAUNDERS CO LTD
DOI: 10.1016/j.rmed.2012.09.017
关键词
Asthma; Inhalers; Chronic obstructive pulmonary disease (COPD)
资金
- Australian Commonwealth Government Department of Health
- Australian Research Council
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Meda
- Nycomed
- Teva
- UCB
- UK MRC
- Sixth EU Framework program for research [FOOD-CT-2004-506378]
- Abdi Ibrahim
- Almirall
- Chiesi
- Innovata Biomed
- Mundipharma
- Orion
- Sandoz
- Truddell
- EPSRC
- MRC
- UK National Health Service
- Aerocrine
- Cipla
- Merck
- Novartis
- Pfizer
- National Institutes of Health (US)
Whilst the inhaled route is the first line administration method in the management of asthma, it is well documented that patients can have problems adopting the correct inhaler technique and thus receiving adequate medication. This applies equally to metered dose inhalers and dry powder inhalers and leads to poor disease control and increased healthcare costs. Reviews have highlighted these problems and the recent European Consensus Statement developed a call to action to seek solutions. This review takes forward the challenge of inhaler competence by highlighting the issues and suggesting potential solutions to these problems. The opportunity for technological innovation and educational interventions to reduce errors is highlighted, as well as the specific challenges faced by children. This review is intended as a policy document, as most issues faced by patients have not changed for half a century, and this situation should not be allowed to continue any longer. Future direction with respect to research, policy needs and practice, together with education requirements in inhaler technique are described. (c) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据